Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

J. Sabari, S. Pisano, K. Gemmler,J. Mueller,R. Bernabe Caro,N. Girard, K. Goto,N. Leighl,Y. Ohe,T. M. Kim,S. -H. Lee, L. Demirdjian, R. Harvey, S. Rudolph, P. Mahadevia,J. Bauml,B. Besse

Journal of Thoracic Oncology（2022）

引用 0|浏览11

暂无评分

摘要

Osimertinib is recommended frontline therapy for patients with EGFR-positive advanced non-small cell lung cancer (NSCLC). This study characterizes real-world treatment patterns and outcomes in frontline and post-osimertinib settings.

查看译文

关键词

Real-world evidence, EGFR-mutant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要